icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Aug 27-29
Digital ILC 2020
Back grey_arrow_rt.gif
Development of a Highly Sensitive Multiplex
Platform Assay to Monitor Low Levels of HBV DNA and pgRNA

  EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Qi Huang, Ran Yan, DaweiCai, Ariel Tang, Xiang Xu and Richard Colonno Assembly Biosciences, Inc., South San Francisco, CA, United States













1) Fan R, Hou J et al. Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy. Clinical Gastroenterology and Hepatology; 2) Carey I, GerschJ, Wang B, et al. Pre-genomic HBV RNA and HBcrAgpredict outcomes in HBeAgnegative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy [published online ahead of print, 2019 Nov 7]. Hepatology. 2019;10.1002/hep.31026; 3) van BömmelF, etcSerum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015;61:66-76; 4) Marcellin P, GaneEJ, FlisiakR, MannsMP, KaitaK, GaggarA, et al. Evidence for ongoing low-level viremia in patients with chronic hepatitis B receiving long-term nucleos(t)ide analog therapy. HEPATOLOGY 2014;60:1093A; 5) Butler EK, etc. Hepatitis B Virus Serum DNA and RNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection. Hepatology. 2018; 68: 2106-2117; 6) Saldanha J, GerlichW., LelieN., Dawson P., HeermannK., Heath A. and The WHO Collaborative Study Group. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sanguinis 2001 80, 63-71; 7) Yuen MF et al. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2019 Nov 8. pii: S2468-1253 (19) 30346-2; 8) Ma, X. et al. Interim Safety and Efficacy Results of the ABI-H0731 Phase 2a Program Exploring the Combination of ABI-H0731 with NucTherapy in Treatment-Naive and Treatment-Suppressed Chronic Hepatitis B Patients. 2019 EASL.